North American Biologicals Inc. said that its QC-HIV QualityAssurance Reagent for in vitro diagnostic use has received Foodand Drug Administration marketing approval.
The company said that its multilevel HIV antibody reagent willreduce to zero the number of analytical errors in AIDS tests.
The Miami company will begin marketing the productimmediately to reference laboratories, blood bank laboratoriesand diagnostic product companies. The company estimates theannual U.S. market at $5 million to $10 million.
Its stock (NASDAQ:NBIO) closed at $4.31, up 38 cents.
(c) 1997 American Health Consultants. All rights reserved.